Clinical Trial Update: Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab [Phase 1]

View source ↗

Summary

Phase 1 study evaluating pembrolizumab to augment graft-versus-leukemia effect in patients with myelodysplastic syndromes and acute myeloid leukemia; the trial …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Myelodysplastic Syndromes, Acute Myeloid Leukemia | Phase 1 | Status: TERMINATED | Results posted: 2025-05-11